Our Pricing

Saxenda Dose Chart: Complete UK Titration Guide

The saxenda dose chart is essential for safe and effective weight loss treatment, guiding patients through a gradual five-week titration from 0.6mg to the full maintenance dose of 3.0mg daily. This structured dose escalation minimises gastrointestinal side effects whilst allowing your body to adjust to liraglutide, the active ingredient in Saxenda. Understanding your saxenda dose chart ensures optimal treatment outcomes and helps you track your progress week by week under the supervision of UK-registered prescribers.

Understanding the Saxenda Dose Chart Weekly Schedule

The saxenda dose chart follows a medically validated five-week titration protocol designed to reduce nausea and improve tolerability[1]. Week 1 begins with 0.6mg injected subcutaneously once daily, typically in the abdomen, thigh, or upper arm. Week 2 increases to 1.2mg, followed by 1.8mg in Week 3, 2.4mg in Week 4, and finally reaching the maintenance dose of 3.0mg in Week 5 and beyond.

This gradual escalation allows GLP-1 receptors in your gastrointestinal tract to adapt progressively, significantly lowering the incidence of common side effects such as nausea, vomiting, and diarrhoea compared to starting at higher doses[1]. Each Saxenda pen contains 18mg of liraglutide across 3ml solution, delivering up to 30 doses at the 0.6mg level or 6 doses at the full 3.0mg maintenance dose.

Clinical experience shows that patients who adhere strictly to the saxenda dose chart experience better weight loss outcomes and fewer treatment discontinuations. If you miss a dose for more than 72 hours, UK prescribers typically recommend restarting the titration from a lower dose to avoid severe gastrointestinal symptoms upon resumption.

Saxenda Dose Chart: Week-by-Week Breakdown

Week 1 of the saxenda dose chart establishes baseline tolerance at 0.6mg daily. Patients should inject at the same time each day, preferably before a meal, to maintain consistent liraglutide plasma levels. Week 2's increase to 1.2mg typically coincides with the first noticeable appetite suppression as GLP-1 receptor activation begins influencing satiety centres in the hypothalamus[2].

By Week 3 at 1.8mg, most patients report reduced food cravings and smaller portion sizes. Week 4's 2.4mg dose often marks the threshold where weight loss accelerates, with clinical trials demonstrating average reductions of 0.5-1kg per week at this stage when combined with a 500kcal daily deficit[2]. Week 5 introduces the full 3.0mg maintenance dose, which should be continued indefinitely for sustained weight management, subject to ongoing prescriber review.

Adjusting Your Saxenda Dose Chart for Side Effects

If gastrointestinal side effects become intolerable at any stage of the saxenda dose chart, UK prescribers may recommend extending a particular dose level for an additional week before escalating. This personalised approach maintains treatment adherence whilst minimising discomfort. Approximately 15-20% of patients require this modified titration schedule[1].

Never increase your dose faster than the standard saxenda dose chart without explicit prescriber approval. Accelerated titration increases the risk of severe nausea, vomiting, and potential dehydration requiring medical intervention. Conversely, remaining at sub-therapeutic doses beyond the recommended schedule may compromise weight loss efficacy.

Clinical Evidence Behind the Saxenda Dose Chart Protocol

The saxenda dose chart titration protocol derives from the SCALE clinical trial programme, which enrolled over 5,000 participants across multiple international sites[3]. These randomised controlled trials established that gradual dose escalation to 3.0mg liraglutide produced superior weight loss compared to placebo, with participants losing an average of 8-9% of initial body weight over 56 weeks[3].

Importantly, the SCALE trials demonstrated that the full 3.0mg maintenance dose was necessary for maximal efficacy—patients maintained at lower doses experienced significantly less weight reduction[3]. This evidence underpins why UK prescribers emphasise completing the full saxenda dose chart escalation rather than stopping at intermediate doses like 1.8mg or 2.4mg.

Post-marketing surveillance data from the MHRA confirms the safety profile observed in clinical trials, with the structured saxenda dose chart reducing adverse event rates compared to faster titration schedules used in earlier liraglutide formulations for diabetes management.

Saxenda Dose Chart Pricing at UK Pharmacies

At Cured Pharmacy, Saxenda is available from £48.00 per pen, with new patients receiving £20 off their first order using code Weightlossnew, bringing the initial cost to £48.00. This represents the cheapest UK price for genuine licensed Saxenda, dispensed following online clinical assessment by UK-registered prescribers.

Each pen lasts between 6 days (at the 3.0mg maintenance dose) and 30 days (at the 0.6mg starting dose), meaning your monthly cost varies depending on where you are in the saxenda dose chart. During Week 1, a single pen suffices for the entire week with doses remaining. By Week 5 and beyond at 3.0mg daily, most patients require approximately 5 pens per month.

Transparent upfront pricing before consultation distinguishes Cured Pharmacy from providers who quote costs only after assessment. All prices include UK delivery, with discreet packaging and next-day delivery options available for approved prescriptions.

Calculating Your Saxenda Dose Chart Monthly Cost

To estimate your monthly expenditure across the saxenda dose chart, consider that the five-week titration requires approximately 2-3 pens total (Week 1 uses minimal volume, whilst Week 5 consumes most of one pen). From Week 6 onwards at the 3.0mg maintenance dose, budget for 5 pens monthly at Cured Pharmacy's competitive UK pricing.

Patients achieving their target weight loss after 12-16 weeks may discuss dose reduction or treatment cessation with their prescriber, potentially lowering ongoing costs. However, clinical guidelines recommend continuing Saxenda at the full maintenance dose whilst active weight loss continues and for weight maintenance thereafter, subject to regular review[4].

Common Questions About the Saxenda Dose Chart

Many patients wonder whether they can skip weeks in the saxenda dose chart to reach the 3.0mg dose faster. This is not recommended—the graduated schedule exists specifically to build physiological tolerance and minimise side effects. Rushing the titration significantly increases nausea severity and treatment discontinuation rates[1].

Another frequent query concerns what to do if side effects persist even at lower doses. UK prescribers may suggest remaining at 1.2mg or 1.8mg for an extended period, though this may reduce overall weight loss efficacy compared to reaching the full 3.0mg maintenance dose. Some patients find that taking Saxenda with food, staying well-hydrated, and avoiding high-fat meals improves tolerability throughout the dose escalation.

Patients also ask whether the saxenda dose chart differs for those with higher BMI. The titration schedule remains identical regardless of starting weight—clinical trials included participants across BMI ranges from 30 to over 40, all following the same five-week protocol[3]. Individual response varies, but the dosing schedule itself is standardised for safety and efficacy.

Maximising Results with Your Saxenda Dose Chart

Adherence to the saxenda dose chart is only one component of successful weight loss—combining liraglutide with a reduced-calorie diet (typically 500-1000kcal daily deficit) and increased physical activity produces optimal outcomes[4]. Clinical trials showed that participants who engaged in structured lifestyle modification alongside Saxenda lost 2-3% more body weight than those relying on medication alone[3].

Track your progress weekly by recording weight, waist circumference, and any side effects experienced at each dose level. This documentation helps your UK prescriber assess treatment response and make informed decisions about continuing, adjusting, or discontinuing Saxenda. Most patients notice appetite suppression within the first two weeks, with measurable weight loss typically beginning by Week 3-4 of the saxenda dose chart.

If you have not lost at least 5% of your initial body weight after 12 weeks at the full 3.0mg maintenance dose, NICE guidelines recommend discontinuing treatment as you are unlikely to achieve clinically meaningful weight loss with continued use[4]. Your prescriber will review your progress at regular intervals to ensure Saxenda remains appropriate and effective for your individual circumstances.

Long-Term Use Beyond the Initial Saxenda Dose Chart

Once you complete the five-week saxenda dose chart and reach 3.0mg daily, this becomes your ongoing maintenance dose for as long as treatment continues. Clinical data supports Saxenda use for up to three years in patients who demonstrate continued benefit, with weight maintenance requiring indefinite therapy in most cases[4].

Discontinuing Saxenda after achieving your target weight typically results in gradual weight regain unless lifestyle modifications are permanently maintained. Discuss long-term treatment plans with your UK prescriber, including periodic reassessment of cardiovascular risk factors, HbA1c (if diabetic), and cost-benefit considerations. Some patients successfully transition to maintenance doses of 1.8mg or 2.4mg after initial weight loss, though this requires individual prescriber evaluation.

Scientific References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
2. Wadden, T. A., Hollander, P., Klein, S., et al. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity, 37(11), 1443-1451.
3. Davies, M. J., Bergenstal, R., Bode, B., et al. (2015). Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes randomized clinical trial. JAMA, 314(7), 687-699.
4. National Institute for Health and Care Excellence. (2020). Liraglutide for managing overweight and obesity (TA664). NICE Technology Appraisal Guidance.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.